Form 4: REGENXBIO CTO Malzahn Receives Equity Awards

REGENXBIO Inc.'s Chief Technology Officer, Craig Malzahn, was granted 65,847 restricted stock units and 35,402 stock options on January 6, 2026.

Summary

• Craig Malzahn, Chief Technology Officer of REGENXBIO Inc. (RGNX), received equity awards on January 6, 2026.
• The awards include 65,847 shares of common stock underlying a time-based restricted stock unit (RSU) award, acquired at a price of $0.00.
• These RSUs will vest in four equal annual installments of 25% on January 6, 2027, 2028, 2029, and 2030, contingent on continuous service.
• Malzahn's beneficial ownership of common stock following this transaction is 82,194 shares.
• Additionally, 35,402 stock options (right to buy) were granted with an exercise price of $14.18 per share.
• The stock options have an expiration date of January 6, 2036.
• 25% of the stock options will vest after 12 months of continuous service, with the remaining balance vesting in equal monthly installments over the subsequent 36 months following January 6, 2027.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive is generally positive for aligning management incentives with shareholder interests and for executive retention. It signals stability in leadership and a long-term commitment.

Positives

• The grant of restricted stock units and stock options aligns the Chief Technology Officer's long-term interests with those of shareholders.
• Equity awards serve as a strong incentive for executive retention and continued service to REGENXBIO Inc.
• The vesting schedules encourage sustained performance and commitment over several years.

Negatives

• The awards do not represent immediate cash compensation for the executive.
• The value realized from the stock options is dependent on the future stock price exceeding the exercise price of $14.18.
• The vesting schedule means the executive must remain with the company for several years to fully realize the value of the awards, which could be seen as a constraint.

Risks

• The value of the equity awards is subject to the market price fluctuations of REGENXBIO Inc.'s common stock.
• Forfeiture of unvested RSUs and stock options if the recipient's continuous service to the Issuer ceases before vesting dates.
• Dilution of existing shareholder value, albeit minor, due to the issuance of new shares upon RSU vesting and option exercise.

Future Outlook

The equity awards, with their multi-year vesting schedules extending to 2030 for RSUs and 2036 for options, indicate a long-term commitment from the Chief Technology Officer to REGENXBIO Inc. and align his future financial incentives with the company's long-term performance and shareholder value creation.

Industry Context

The granting of restricted stock units and stock options is a common practice in the biotechnology and pharmaceutical industries for executive compensation. This approach is widely used to attract, retain, and motivate key talent by linking their compensation directly to the company's stock performance and long-term success.

Comparison to Industry Standards

• The structure of these equity awards, including multi-year vesting schedules for both RSUs and stock options, is consistent with standard executive compensation practices observed across the biotechnology and broader life sciences sectors.
• While the filing does not provide specific comparative data for other companies' executive compensation packages, the use of performance-based (continuous service) and time-based vesting is a widely adopted mechanism to align executive incentives with long-term shareholder value.

Stakeholder Impact

• Shareholders: Potential long-term benefit from aligned management incentives and executive retention, contributing to stable leadership and strategic execution.
• Employees (Craig Malzahn): Significant long-term compensation opportunity, contingent on continued service and company performance.

Next Steps

• Continued service by the Chief Technology Officer to ensure vesting of RSUs and stock options on their respective schedules.
• Monitoring of REGENXBIO Inc.'s stock performance, which will impact the ultimate value of these equity awards.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a key executive, which is a positive for management retention and alignment of interests. However, it does not contain information that would fundamentally alter the investment thesis for REGENXBIO Inc., thus a 'hold' recommendation is appropriate based solely on this filing. Investors should consider broader company fundamentals and market conditions.

Keywords

REGENXBIO, RGNX, Craig Malzahn, Chief Technology Officer, Stock Options, Restricted Stock Units, RSU, Equity Compensation, Insider Transaction, Form 4, Executive Compensation